Skip to main content
Betta Pharmaceuticals Co.,Ltd logo

Betta Pharmaceuticals Co.,Ltd — Investor Relations & Filings

Ticker · 300558 ISIN · CNE100002DD9 LEI · 8368009YF4Y6NC7HVB09 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,656 across all filing types
Latest filing 2018-07-19 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300558

About Betta Pharmaceuticals Co.,Ltd

https://www.bettapharma.com

Betta Pharmaceuticals Co.,Ltd. focuses on the research, development, and commercialization of innovative oncology medications. The organization specializes in targeted therapies, particularly for the treatment of lung cancer and other solid tumors. Its portfolio includes Icotinib, a small-molecule EGFR tyrosine kinase inhibitor, and Ensartinib, an ALK inhibitor designed for non-small cell lung cancer. The company operates a comprehensive R&D infrastructure dedicated to molecular biology, medicinal chemistry, and clinical development. By prioritizing precision medicine, the firm aims to deliver high-quality therapeutic solutions that address complex oncological challenges. Its pipeline encompasses a diverse range of candidates, including small molecules and biologics, aimed at improving patient outcomes through advanced scientific innovation.

Recent filings

Filing Released Lang Actions
关于Vorolanib（CM082）和特瑞普利（JS001）联用的临床试验申请获得受理的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by a pharmaceutical company regarding the acceptance of a clinical trial application by the National Medical Products Administration (国家药品监督管理局). It details the clinical trial drugs, their research status, and the implications for the company. The document is relatively short (2021 characters) and serves as an official notice about regulatory acceptance rather than a detailed report or financial statement. It does not contain financial data, earnings, or management discussion. It is not a report publication announcement since it does not mention a report being attached or published. The content fits best under a general regulatory announcement category about clinical trial application acceptance, which aligns with Regulatory Filings (RNS).
2018-07-19 Chinese
2018年半年度业绩预告
Regulatory Filings Classification · 95% confidence The document is a performance forecast for the half-year period ending June 30, 2018, indicating expected net profit decline and reasons for the change. It explicitly states that the forecast is preliminary, unaudited, and that detailed financial data will be disclosed in the 2018 half-year report. The document is short (977 characters) and serves as an announcement of expected financial results rather than a full interim report containing actual financial statements or substantive analysis. Therefore, it is best classified as a Regulatory Filing (RNS) since it does not contain the full interim report but only a performance forecast announcement.
2018-07-13 Chinese
简式权益变动报告书
Major Shareholding Notification Classification · 100% confidence The document is titled as a "简式权益变动报告书" which translates to a "Simplified Equity Change Report" or "Simplified Report on Changes in Shareholding." It details the reduction in shareholding by Beta Pharma Inc. in 贝达药业股份有限公司 (Beta Pharma Inc.'s shareholding in Beta Pharma Co., Ltd.). The document includes information about the shareholder, the nature of the shareholding change, the number of shares before and after the change, and the legal compliance statements. It does not contain financial statements, earnings data, or management discussion of financial results. It is a formal notification of a change in major shareholding, specifically noting that the shareholding dropped below 5%. This fits the definition of a Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels crossing thresholds. The document is about a shareholding change and not about a report publication or other types of filings. Therefore, the correct classification is MRQ with high confidence.
2018-07-10 Chinese
关于股东减持公司股份后持股比例低于5%的提示性公告
Major Shareholding Notification Classification · 100% confidence The document is a notification about a shareholder (Beta Pharma Inc.) reducing its shareholding in the company below the 5% threshold. It details the number of shares reduced, the percentage of total shares, the timeline of the reduction, and compliance with regulatory requirements. It includes tables showing shareholding before and after the reduction and mentions related announcements and commitments by the shareholder. There is no financial data, earnings information, or management discussion. The document is a formal announcement of a major shareholding change, specifically a shareholder reducing their stake below 5%, which fits the definition of a Major Shareholding Notification (MRQ). The document length is 2656 characters, which is consistent with a notification rather than a full report. Therefore, the correct classification is MRQ.
2018-07-10 Chinese
关于公司聘任高管的公告
Board/Management Information Classification · 100% confidence The document is an announcement from 贝达药业股份有限公司 regarding the appointment of senior management personnel. It details the names, roles, and qualifications of the newly appointed executives, along with compliance statements and background checks. There is no financial data, earnings information, or report publication mentioned. The content focuses solely on management changes, which fits the category of Board/Management Information (MANG). The document length is 2736 characters, which is consistent with an announcement rather than a full report.
2018-07-10 Chinese
独立董事关于第二届董事会第二十三次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent directors' opinion on the nomination of senior management personnel at a board meeting of Betta Pharmaceuticals Co., Ltd. It references compliance with company law, the company's articles, and independent director work systems. The content focuses on the nomination and approval process of senior management candidates, not on financial results, audit opinions, or regulatory filings. It is a formal statement related to board/management changes. Therefore, it fits the category of Board/Management Information (MANG). The document length is short but contains substantive content about management nominations, not just an announcement or certification.
2018-07-10 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.